Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

benzinga.com/general/biotech/25/05/45624650/why-is-neuropace-stock-falling-after-epilepsy-treatment-study-data

NeuroPace, Inc. (NASDAQ:NPCE) released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generalized epilepsy (IGE).
The study met its primary 12-week post-implant safety…

This story appeared on benzinga.com, 2025-05-27 16:48:38.
The Entire Business World on a Single Page. Free to Use →